India has embarked on a third and final phase of clinical vaccine trials against the coronavirus Covaxin. The drug was developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR), according to the TV channel NDTV

Among the volunteers was the Vice-Chancellor of the Aligarh Muslim University (AMU) Tariq Mansur.

The vaccine is planned to be tested in 25 medical centers across the country among 26 thousand volunteers. Test takers are paid travel and other required benefits.

The Covaxin vaccine was approved after the successful completion of the first two phases of trials, which involved about 800 people.

Rector Mansur Twitter urged citizens to volunteer to register to participate in “groundbreaking research to develop better treatments and treatments.”

Two more vaccines are currently being tested in India: Covishield (developed by Oxford University and the British-Swedish company AstraZeneca) and ZyCoV-D (developed by the Indian pharmaceutical company Zydus Cadila).

© The Eastern Herald
No oligarch or politician dictates to us how to write about any subject. We need your support. Please contribute whatever you can afford. Click here to make your donation.
Follow us on:
Eastern Herald on Google News
News Room
The Eastern Herald’s Editorial Board is responsible for the stories published under this byline. That includes editorials, news stories, letters to the editor, and multimedia features on